The history and potential future of monoclonal antibody therapeutics development and manufacturing in four eras
Therapeutic monoclonal antibody (mAb) development and the processes for manufacturing drug substance have evolved since the first approval of the mAb in 1986. As the past is often the prologue to the future, the history of these technologies has been classified here into three eras, leading to specu...
Saved in:
Main Author: | Brian Kelley |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2024-12-01
|
Series: | mAbs |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2024.2373330 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost and supply considerations for antibody therapeutics
by: Chun Chen, et al.
Published: (2025-12-01) -
New era towards autonomous additive manufacturing: a review of recent trends and future perspectives
by: Haolin Fan, et al.
Published: (2025-01-01) -
Physiochemical and functional evaluation of the first-in-class anti-cancer IgE antibody drug, MOv18, through process development and good manufacturing practice production
by: Heather J Bax, et al.
Published: (2025-12-01) -
Sustainability as a determinant of cost management in the accounts of a manufacturing Industry
by: M. Stępień
Published: (2019-08-01) -
Development of an Adaptable Qualification Test Set for Personnel Involved in Visual Inspection Procedures of Parenteral Drug Products Manufactured Under Good Manufacturing Practice Conditions in Hospital Pharmacy Compounding Facilities
by: Tessa van den Born-Bondt, et al.
Published: (2025-01-01)